Review summary
Teaching objective: Primary care for a 57-year-old physician by training, now a political leader, who presents with a right upper quadrant mass and weight loss: the work-up of a solid liver mass (multiphase imaging, alpha-fetoprotein, CA 19-9 and CEA, hepatitis B and C serology, liver function with Child-Pugh and ALBI scoring, and biopsy because a mass in a non-cirrhotic liver cannot be diagnosed by imaging alone, following the AASLD 2023 guidance), the finding of a gallbladder adenocarcinoma invading the liver rather than a primary liver cancer (mirroring the historical conflict between the operative and autopsy findings), staging laparoscopy and the multidisciplinary tumor board on the NCCN biliary tract cancers guideline, first-line gemcitabine, cisplatin and durvalumab with its monitoring, hepatitis B reactivation monitoring in resolved infection, early specialist palliative care, and the care of a physician as a patient.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| November 12, 1866 | Born in Cuiheng Village. | CLM-0001 |
| About 1879 (age thirteen) | Began his studies in Honolulu. | CLM-0002 |
| 1886 | Began studying Western medicine at the Boji Hospital in Guangzhou. | CLM-0003 |
| 1887 | Entered the College of Medicine for Chinese in Hong Kong. | CLM-0003 |
| July 23, 1892 | Received his medical diploma at the college's first graduation ceremony. | CLM-0003 |
| 1893 | Moved his medical practice from Macau to Guangzhou. | CLM-0004 |
| 1894 | Founded the China Revival Society in Honolulu; left medicine for politics. | CLM-0004, CLM-0005 |
| 1905 | Founded the Chinese Revolutionary League in Tokyo. | CLM-0005 |
| January 1, 1912 | Became Provisional President of the Republic of China in Nanjing. | CLM-0005 |
| January 1924 | Presided over the First National Congress of the Kuomintang in Guangzhou. | CLM-0005 |
| December 31, 1924 | Arrived in Beijing in poor health. | CLM-0006 |
| January 26, 1925 | Admitted to the Peking Union Medical College Hospital; exploratory laparotomy found carcinoma involving the liver. | CLM-0007, CLM-0008, CLM-0010 |
| February 18, 1925 | Left the hospital against advice. | CLM-0008 |
| March 12, 1925 | Died in Beijing. | CLM-0009, CLM-0010 |
| March 13, 1925 | Limited autopsy reported adenocarcinoma of the gallbladder with spread to the liver and beyond. | CLM-0011 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Sun Yat-sen was born on November 12, 1866, into an ordinary farming family in Cuiheng Village. He was called Dixiang in childhood and also had the names Mingwen, Deming and Rixin; the name Yat-sen came into use while he was in Japan. The birth date used for the synthetic date of birth. |
confirmed | Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports |
| D | He went to a private school at nine, studied in Honolulu from the age of thirteen, and returned home at seventeen. Social history. |
confirmed | Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports |
| D | He began studying Western medicine at the Boji Hospital in Guangzhou in 1886 and in 1887 transferred to the College of Medicine for Chinese in Hong Kong, as one of its twelve students; his teachers included Patrick Manson. He was one of two students who passed the graduation examination in 1892 and received his diploma at the college's first graduation ceremony on July 23, 1892. The anchor for the modern episode's physician-as-patient theme. |
confirmed | Chow YYN. From medicine to politics (Dr Sun Yat-sen Oration) supports Sun Yat-sen chronology supports |
| D | After graduating he practiced medicine in Macau, first at the Kiang Wu Hospital and then in a dispensary of his own, and then in Guangzhou, opening pharmacies that offered Chinese and Western medicines; about two years after graduating he gave up medicine for politics. He practiced for about two years; the modern episode treats him as a physician by training who left practice decades ago. |
confirmed | Chow YYN. From medicine to politics (Dr Sun Yat-sen Oration) supports Sun Yat-sen chronology supports |
| D | In 1894 he founded the China Revival Society in Honolulu; in 1905 he founded the Chinese Revolutionary League in Tokyo; on New Year's Day 1912 he became Provisional President of the Republic of China in Nanjing; and in January 1924 he presided over the First National Congress of the Kuomintang in Guangzhou. Social history: the anchor for the modern work as the leader of a political organization. |
confirmed | Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports Sun Yat-sen chronology supports |
| D | In the autumn of 1924, after the Beijing Coup, he was invited to Beijing to discuss state affairs, and he arrived in Beijing in poor health on the last day of 1924. After the true-frame episode; history only. |
confirmed | Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports Liu Ruiheng supports |
| D | Several months before his operation in January 1925 a mass had been noted in his right upper abdomen and was thought to be his liver; it grew larger shortly before surgery. At the preoperative examination he had no jaundice and not much loss of weight. The anchor for the modern presenting problem, a right upper quadrant mass. The month the mass was first noted is not recorded. |
probable | Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports |
| D | He was admitted to the Peking Union Medical College Hospital on January 26, 1925, too ill to eat, and had an exploratory laparotomy that day by Adrian S. Taylor, the head of surgery, which found extensive involvement of the liver by carcinoma. He was treated with radium for the rest of his stay, left the hospital against advice on February 18, 1925, and was then treated by old-style Chinese doctors while his condition declined. History only; after the true-frame episode. |
confirmed | Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports Liu Ruiheng supports |
| D | He died in Beijing on March 12, 1925. History only. |
confirmed | Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports Sun Yat-sen chronology supports |
| R | His fatal illness has long been described as liver cancer, the diagnosis taken from the findings at the laparotomy; the museum at his birthplace states that he died of liver cancer. Recorded as the traditional account; a later review of the autopsy report disputes a primary liver cancer (CLM-0011). |
disputed | Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death disputes |
| R | A limited autopsy at the Peking Union Medical College Hospital on March 13, 1925, by James R. Cash, reported adenocarcinoma of the gallbladder with obstruction of the cystic duct, direct extension to the liver and diaphragm, and metastases to the lungs, peritoneum, ileum and colon, with healed cholecystitis, gallstones, generalized arteriosclerosis, healed calcified tuberculosis of the lungs, emphysema, ascites and roundworm infestation. A 2016 review concludes that gallbladder adenocarcinoma, not a primary liver cancer, caused his death. The anchor for the modern diagnosis: a gallbladder adenocarcinoma that invades the liver and presents as a liver mass. The review rests on the autopsy report; the original slides were not re-examined in the fetched source. |
probable | Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | active | CLM-0007 |
| S | Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | both_with_link | CLM-0007, CLM-0008, CLM-0010, CLM-0011 |
| S | Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | active | |
| S | Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable | active | confirmed | both_with_link | CLM-0011 |
| S | Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 7.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL (low) Reference 13.2-17.1 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 342 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 98 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-05-04 | Albumin [Mass/volume] in Serum or Plasma | 3.4 g/dL (low) Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-05-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.2-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-05-04 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 212 U/L (high) Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-04 | INR in Platelet poor plasma by Coagulation assay | 1 Reference 0.9-1.1 |
http://loinc.org · 6301-6 |
| S | 2026-05-04 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 3.2 ng/mL Reference <=8.3 ng/mL |
http://loinc.org · 1834-1 |
| S | 2026-05-04 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 412 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 2026-05-04 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 8.6 ng/mL (high) Reference Up to 3.0 ng/mL in non-smokers |
http://loinc.org · 2039-6 |
| S | 2026-05-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-05-04 | ECOG Performance Status score | 1 | http://loinc.org · 89247-1 |
| S | 2026-05-18 | ECOG Performance Status score | 1 | http://loinc.org · 89247-1 |
| S | 2026-06-01 | Leukocytes [#/volume] in Blood by Automated count | 7.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-06-01 | Neutrophils [#/volume] in Blood by Automated count | 4.9 10*3/uL Reference 1.8-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-06-01 | Hemoglobin [Mass/volume] in Blood | 12.2 g/dL (low) Reference 13.2-17.1 g/dL |
http://loinc.org · 718-7 |
| S | 2026-06-01 | Platelets [#/volume] in Blood by Automated count | 318 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-06-01 | Magnesium [Mass/volume] in Serum or Plasma | 2 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2026-06-01 | Albumin [Mass/volume] in Serum or Plasma | 3.4 g/dL (low) Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-06-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.2-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 236 U/L (high) Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-06-01 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-06-01 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 498 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-06-01 | ECOG Performance Status score | 1 | http://loinc.org · 89247-1 |
| S | 2026-08-03 | Leukocytes [#/volume] in Blood by Automated count | 4.6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-08-03 | Neutrophils [#/volume] in Blood by Automated count | 2.4 10*3/uL Reference 1.8-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-08-03 | Hemoglobin [Mass/volume] in Blood | 10.9 g/dL (low) Reference 13.2-17.1 g/dL |
http://loinc.org · 718-7 |
| S | 2026-08-03 | Platelets [#/volume] in Blood by Automated count | 188 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-08-03 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-08-03 | Potassium [Moles/volume] in Serum or Plasma | 4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-08-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 97 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-08-03 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-08-03 | Magnesium [Mass/volume] in Serum or Plasma | 1.7 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2026-08-03 | Albumin [Mass/volume] in Serum or Plasma | 3.6 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-08-03 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.2-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-08-03 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 158 U/L (high) Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-08-03 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-08-03 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-08-03 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-08-03 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 168 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 2026-08-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-08-03 | ECOG Performance Status score | 1 | http://loinc.org · 89247-1 |
| S | 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 4.3 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-10-26 | Neutrophils [#/volume] in Blood by Automated count | 2.1 10*3/uL Reference 1.8-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 10.7 g/dL (low) Reference 13.2-17.1 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-26 | Platelets [#/volume] in Blood by Automated count | 176 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.1 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.95 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 93 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-26 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-10-26 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 mg/dL (low) Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2026-10-26 | Albumin [Mass/volume] in Serum or Plasma | 3.7 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-10-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.2-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-10-26 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 141 U/L (high) Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-26 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-10-26 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 121 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-10-26 | ECOG Performance Status score | 1 | http://loinc.org · 89247-1 |
| S | 2026-09-02 | Leukocytes [#/volume] in Blood by Automated count | 3.9 10*3/uL (low) Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-09-02 | Neutrophils [#/volume] in Blood by Automated count | 1.6 10*3/uL (low) Reference 1.8-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2026-09-02 | Hemoglobin [Mass/volume] in Blood | 10.6 g/dL (low) Reference 13.2-17.1 g/dL |
http://loinc.org · 718-7 |
| S | 2026-09-02 | Platelets [#/volume] in Blood by Automated count | 162 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-05-04 | Body height | 165 cm | 8302-2 | S |
| 2026-05-04 | Body weight | 61 kg | 29463-7 | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 22.4 kg/m2 | 39156-5 | S |
| 2026-05-04 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-05-04 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-05-04 | Heart rate | 88 /min | 8867-4 | S |
| 2026-05-04 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-04 | Body temperature | 36.9 Cel | 8310-5 | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-18 | Body height | 165 cm | 8302-2 | S |
| 2026-05-18 | Body weight | 60.6 kg | 29463-7 | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 22.3 kg/m2 | 39156-5 | S |
| 2026-05-18 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-05-18 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-05-18 | Heart rate | 86 /min | 8867-4 | S |
| 2026-05-18 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-18 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-01 | Body height | 165 cm | 8302-2 | S |
| 2026-06-01 | Body weight | 60 kg | 29463-7 | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 22 kg/m2 | 39156-5 | S |
| 2026-06-01 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-06-01 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-06-01 | Heart rate | 84 /min | 8867-4 | S |
| 2026-06-01 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-01 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-03 | Body height | 165 cm | 8302-2 | S |
| 2026-08-03 | Body weight | 59.2 kg | 29463-7 | S |
| 2026-08-03 | Body mass index (BMI) [Ratio] | 21.7 kg/m2 | 39156-5 | S |
| 2026-08-03 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-08-03 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-08-03 | Heart rate | 82 /min | 8867-4 | S |
| 2026-08-03 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-08-03 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-26 | Body height | 165 cm | 8302-2 | S |
| 2026-10-26 | Body weight | 59.6 kg | 29463-7 | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 21.9 kg/m2 | 39156-5 | S |
| 2026-10-26 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-10-26 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-10-26 | Heart rate | 80 /min | 8867-4 | S |
| 2026-10-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-02 | Body height | 165 cm | 8302-2 | S |
| 2026-09-02 | Body weight | 59 kg | 29463-7 | S |
| 2026-09-02 | Body mass index (BMI) [Ratio] | 21.7 kg/m2 | 39156-5 | S |
| 2026-09-02 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-09-02 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-09-02 | Heart rate | 90 /min | 8867-4 | S |
| 2026-09-02 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-02 | Body temperature | 37.4 Cel | 8310-5 | S |
| 2026-09-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-21 | Body height | 165 cm | 8302-2 | S |
| 2026-09-21 | Body weight | 59.4 kg | 29463-7 | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 21.8 kg/m2 | 39156-5 | S |
| 2026-09-21 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-09-21 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-09-21 | Heart rate | 80 /min | 8867-4 | S |
| 2026-09-21 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Physician by training: studied Western medicine in Guangzhou and Hong Kong and practiced for about two years in Macau and Guangzhou before leaving medicine for public life decades ago; now leads a national political organization, writes and speaks widely, and travels often
- S Never smoked; drinks alcohol rarely, at formal dinners; no other substance use
- S Lives with his wife in a rented apartment near his organization's offices; he chooses who joins him at visits and what they are told. Speaks Cantonese, Mandarin and English and chose English for his visits; an interpreter is offered for any family meeting
- S Strengths and supports: a clear, analytical mind and his own medical training; a strong sense of purpose in his work; a wide circle of colleagues
Functional status
- S Independent in all activities; still works full days but tires by evening; walks 2 km without stopping
Mental status
- S Alert, composed and precise; asks to see the ultrasound images himself; worried that the mass is a cancer; PHQ-2 1
Allergies and medications
Allergies
- S No known allergy
Medications
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day
- S Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle
- S Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle
- S Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle
- S Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea
- S Magnesium oxide 400 mg oral tablet, one tablet by mouth daily
Procedures and immunizations
Procedures
- S Ultrasound of the abdomen
- S Multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis
- S MRI of the liver with MRCP
- S Ultrasound-guided core biopsy of the liver mass
- S Multidisciplinary hepatobiliary tumor board review before staging
- S Staging laparoscopy
- S Biopsy of peritoneal nodules at staging laparoscopy
- S Implanted venous access port placed under the same anesthetic
- S Multidisciplinary hepatobiliary tumor board review after staging laparoscopy
- S Restaging contrast CT of the chest, abdomen and pelvis after three cycles
- S Restaging contrast CT of the chest, abdomen and pelvis after seven cycles
- S Advance care planning conversation, about 25 minutes
Immunizations
- S 2026-09-21: Influenza vaccine, 2026-2027 season (inactivated)
- S 2026-09-21: COVID-19 vaccine, 2026-2027 formula
- S 2026-09-21: Pneumococcal conjugate vaccine (PCV20), for immunosuppression by chemotherapy
- S 2026-10-26: Recombinant zoster vaccine, first of two doses
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Tissue diagnosis and complete staging within four weeks of the first visit | 2026-06-01 | completed | Biopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks |
| Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1) | 2026-10-26 | completed | Ache 0 to 2 of 10 on acetaminophen as needed; ECOG 1 throughout |
| Weight held within 2 kg of the weight at the start of treatment | 2026-10-26 | completed | 60.0 kg at cycle 1 and 59.6 kg at cycle 8 |
| Goals of care and a health care agent documented, and revisited as treatment changes | 2026-09-21 | completed | Agent named and goals recorded with palliative care and at the preventive visit |
| Complete first-line chemoimmunotherapy without grade 3 or higher toxicity | 2026-10-26 | active | Seven cycles given by the last visit with grade 1 toxicity only; the eighth started that day |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Work-up of the liver mass: multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis; MRI of the liver with MRCP if CT does not settle the origin; alpha-fetoprotein, CA 19-9 and CEA; hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody; liver function with Child-Pugh and ALBI scoring; and image-guided core biopsy, because a mass in a liver without cirrhosis cannot be diagnosed by imaging alone | completed | GL-AASLD-HCC-2023, GL-NCCN-BIL-2026 |
| Medical oncology consultation for a solid liver mass with weight loss: diagnosis, staging, multidisciplinary tumor board review, and treatment | completed | GL-NCCN-BIL-2026, GL-AASLD-HCC-2023 |
| Symptom care during the work-up: acetaminophen up to 3,000 mg a day, small frequent meals with a dietitian's advice, weight at every visit, and a same-day call for jaundice, fever, vomiting, dark urine or worse pain; results shared with him in full as they arrive, by one coordinating clinician | completed | GL-NCCN-BIL-2026 |
| Staging laparoscopy before any attempt at resection, with biopsy of any peritoneal disease and an implanted port under the same anesthetic; if no metastases, extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy; comprehensive genomic profiling of the biopsy tissue (HER2, mismatch repair and microsatellite status, BRAF, FGFR2, IDH1, NTRK, RET, KRAS, tumor mutational burden) | completed | GL-NCCN-BIL-2026 |
| Hepatitis B reactivation monitoring for resolved infection (surface antigen negative, core antibody positive, HBV DNA undetectable): HBV DNA and ALT every 3 months during treatment and for at least 6 to 12 months after, with entecavir started promptly if HBV DNA becomes detectable or surface antigen reappears | completed | GL-ASCO-HBV-2020 |
| First-line systemic therapy for stage IVB gallbladder adenocarcinoma: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab 1,500 mg every 4 weeks until progression or unacceptable toxicity; blood count, creatinine, magnesium and liver tests before each dose; TSH every cycle; CA 19-9 each cycle; CT of the chest, abdomen and pelvis every 2 to 3 months; teaching on immune-related side effects; ondansetron at home | completed | GL-NCCN-BIL-2026, GL-TOPAZ1-2022, GL-ASCO-IRAE-2021 |
| Specialist palliative care alongside cancer treatment from the diagnosis of advanced disease: symptoms, nutrition, coping, goals of care, a health care agent, and a family meeting if and when he chooses | completed | GL-ASCO-PALL-2017 |
| Magnesium oxide 400 mg by mouth daily for cisplatin-related low magnesium, rechecked with each dose; durvalumab maintenance every 4 weeks after the eighth cycle, with restaging CT every 2 to 3 months | completed | GL-NCCN-BIL-2026, GL-TOPAZ1-2022 |
Planned encounters
- 2026-05-04 — New patient with a right upper abdominal mass, aching and weight loss: work-up of a liver mass, symptom care, and how he wants to receive results (ENC-001)
- 2026-05-18 — Biopsy and imaging results and medical oncology consultation; diagnosis, staging plan, and hepatitis B status (ENC-002)
- 2026-06-01 — Staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative care (ENC-003)
- 2026-08-03 — Before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling result (ENC-004)
- 2026-09-02 — Same-day sick visit for a cold during chemoimmunotherapy (ENC-006, unscheduled)
- 2026-09-21 — Periodic adult preventive visit (ENC-007)
- 2026-10-26 — Before cycle 8: restaging CT, toxicity review, low magnesium, and the plan for maintenance durvalumab (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Sick Visit
- Progress note 06 — Preventive Visit
- Progress note 07 — Focused Visit (Care-plan review)
- Medical Oncology referral
- Medical Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Preventive Visit (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Medical Oncology referral (XML)
- Medical Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death | Chinese Journal of Cancer 2016;35(1):81 (PMID 27586157) | scholarly |
| SRC-0002 | Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography | Museum of Dr. Sun Yat-sen (Cuiheng) | biography |
| SRC-0003 | Chow YYN. From medicine to politics (Dr Sun Yat-sen Oration) | The Hong Kong Practitioner 2007;29(7), Hong Kong College of Family Physicians | scholarly |
| SRC-0004 | Sun Yat-sen chronology | Museum of Dr. Sun Yat-sen (Cuiheng) | biography |
| SRC-0005 | Liu Ruiheng | Tianjin University | biography |
| SRC-0006 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the liver-mass work-up in a non-cirrhotic liver (biopsy rather than imaging criteria), the gallbladder primary, the staging laparoscopy, gemcitabine, cisplatin and durvalumab dosing and monitoring, hepatitis B monitoring rather than prophylaxis for resolved infection, and the timing of palliative care. |
| provenance review | not_started | Barth and Chen 2016 (PMC5009495), the Museum of Dr. Sun Yat-sen biography and chronology, Chow 2007 (The Hong Kong Practitioner), and the Tianjin University biography of Liu Ruiheng logged. The liver cancer and gallbladder cancer accounts are both recorded as R claims. |
| safe messaging review | not_started | A national founding figure; the modern episode adds no claim about his real health beyond the cited sources, his hepatitis B serology is labeled synthetic, and no decision or statement is attributed to his wife or other real people. His death is recorded as history only. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.